Attention-Deficit/Hyperactivity Disorder Clinical Practice Guidelines (AAP, 2019)

American Academy of Pediatrics

This is a quick summary of the guidelines without analysis or commentary. For more information, go directly to the guidelines by clicking the link in the reference.

November 04, 2019

Guidelines for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder were published in 2019 by the American Academy of Pediatrics (AAP).[1]

Any child or adolescent age 4 to 18 years who presents with academic or behavioral problems and symptoms of inattention, hyperactivity, or impulsivity should be evaluated for ADHD.

In evaluating a child or adolescent for ADHD, the primary care clinician (PCC) should screen for comorbid conditions, including emotional or behavioral conditions, developmental conditions, and physical conditions.

For preschool-aged children (ages 4 to 6 years) with ADHD, the PCC should prescribe evidence-based parent training in behavior management (PTBM) and/or behavioral classroom interventions as the first line of treatment.

If behavioral interventions don't work, methylphenidate may be considered.

For elementary and middle school-aged children (ages 6 to 12 years) with ADHD, the PCC should prescribe FDA-approved medications for ADHD, along with PTBM and/or behavioral classroom intervention.

For adolescents (ages 12 to 18 years) with ADHD, the PCC should prescribe FDA-approved medications for ADHD with the adolescent’s assent. The PCC is encouraged to prescribe evidence-based training interventions and/or behavioral interventions as well.

For more Clinical Practice Guidelines, go to Guidelines.

For more information, go to Attention-Deficit/Hyperactivity Disorder.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.